Strategic collaborations are a key component of KAI’s business strategy to explore the potential therapeutic applications of our selective PKC modulation technology. 
   

Research Programs
KAI is open to exploring research collaborations which leverage our selective PKC modulation platform to explore the potential of PKC isozymes as therapeutic targets across a range of indications. With full pharmacology, peptide chemistry and preclinical/clinical development expertise in-house, KAI has the capabilities to support all types of collaboration structures, from technology licensing to full research and development collaborations. For information regarding our current areas of interest, please visit our Research Programs page. For a full description of the addressable disease targets that our platform affords, please visit our About Protein Kinase C page.

Partnering Contact
For business development inquiries, please contact: This email address is being protected from spam bots, you need Javascript enabled to view it